The Cybersecurity Threat and Vulnerability Information Sharing Platform of the Ministry of Industry and Information Technology recently monitored and found that some instances of the OpenClaw (commonly known as "Lobster") open-source AI agent have a high security risk under default or improper configurations, making them susceptible to cyberattacks, information leaks, and other security issues. It is recommended that relevant units and users thoroughly check the public exposure, permission configurations, and credential management when deploying and using OpenClaw, close unnecessary public access, improve security mechanisms such as identity authentication, access control, data encryption, and security auditing, and continuously pay attention to official security announcements and hardening recommendations to prevent potential cybersecurity risks.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











